ReviewCancers2026
The Central Role of Imaging in Renal Cell Carcinoma: A Comprehensive Review of Tumor Aggressiveness, Histology, and Radiomics.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma encompasses a heterogeneous group of kidney tumors with wide variations in biological behavior, histologic subtype, and clinical aggressiveness. Accurate preoperative characterization is essential for management, yet remains challenging because benign, indolent, and aggressive lesions often show overlapping imaging features. CT is the most widely used modality for renal mass evaluation, offering broad availability, high spatial resolution, and multiphasic acquisition. This comprehensive narrative review summarizes current evidence on CT-based characterization of renal cell carcinoma, radiologic-pathologic correlation, imaging markers of tumor aggressiveness, renal mass biopsy, and radiomics. Radiomics and other quantitative imaging approaches may complement conventional imaging by capturing tumor heterogeneity and biologically relevant features; however, most studies remain retrospective, single-center, and methodologically heterogeneous. Multicenter validation, standardized acquisition and segmentation, transparent reporting, and demonstration of added clinical value are required before these methods can be implemented in routine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.